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A B S T R A C T
Background
Recent studies in acute stroke patients have shown an association between body temperature and prognosis.
Objectives
Our objective was to assess the effects of cooling when applied to patients with acute ischaemic stroke or primary intracerebral
haemorrhage.
Search strategy
We searched the Cochrane Stroke Group’s trial register (last searched in March 1999), plus MEDLINE searched up to November
1998 and EMBASE searched from January 1980 to November 1998. We contacted investigators, pharmaceutical companies and
manufacturers of cooling equipment in this field.
Selection criteria
All completed randomised controlled trials or controlled clinical trials, published or unpublished, where cooling therapy (therapy given
by physical devices or antipyretic drugs primarily to lower body temperature independently of basal temperature at the beginning of
treatment) was applied up to two weeks of an acute ischaemic stroke or primary intracerebral haemorrhage.
Data collection and analysis
Two reviewers independently searched for relevant trials.
Main results
No randomised trials or controlled trials were identified; one placebo-controlled trial of metamizol is currently underway.
Authors’ conclusions
There is currently no evidence from randomised trials to support the routine use of physical or chemical cooling therapy in acute stroke.
Since experimental studies showed a neuroprotective effect of hypothermia in cerebral ischaemia, and hypothermia appears to improve
the outcome in patients with severe closed head injury, trials with cooling therapy in acute stroke are warranted.
P L A I N L A N G U A G E S U M M A R Y
No evidence to support the use of cooling therapy within the first two weeks after a stroke
Stroke is the third most common cause of death and a leading cause of long-term disability worldwide. Extreme cooling of the body
temperature (hypothermia) may possibly protect the nervous system from damage during stroke and some evidence has suggested that
people with a lower body temperature at the time of a stroke do better later than those with a higher temperature. Cooling is used in
neurosurgery, open-heart surgery, and severe closed-head injury to protect patients. The authors of this Cochrane review looked for
evidence that cooling the body would benefit patients during or in the two weeks after a stroke. They looked for studies on the use
of physical or chemical cooling therapy on patients within two weeks of having a stroke. Physical cooling techniques would include
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cooling blankets, use of ice, fans, or other devices. Chemical cooling techniques would include drugs used to reduce fever, like aspirin
or acetaminophen. The authors looked for studies on two types of stroke patients: those with acute ischaemic stroke (when a blood
clot blocks blood flow to the brain), and those with primary intracerebral haemorrhage (when a blood vessel in the brain ruptures).
The review authors did not find any randomized controlled trials or controlled clinical trials on cooling therapy for stroke. These types
of studies are the best type of evidence for whether a therapy works, because they limit the errors that may be introduced into a study.
The authors did find a major trial in progress, using the drug metamizol for cooling. The review authors could not recommend the use
of cooling therapy for stroke patients since there was no completed research that showed this therapy to be effective and safe.
B A C K G R O U N D
Stroke is the third commonest cause of death after coronary artery
disease and all cancers, not only in developed countries but world
wide (Murray 1997) and one of the leading causes of long-term
disability.
Despite their effectiveness in animal models of stroke, clinical
trials of neuroprotective agents in humans have provided disap-
pointing results (Ad Hoc Consensus1998) and so, other means
of neuroprotection should be sought. There are references from
decades ago that show in animals that hypothermia confers pro-
tection against the neuronal injury produced by episodes of tran-
sient cerebral ischaemia (Mellergard 1992). The mechanisms are
not fully understood. Hypothermia is known to decrease the cere-
bral metabolic rate, and there is good evidence that at least some
of the neuroprotection of hypothermia is due to the associated
decrease of metabolic demand (Michenfelder 1988). Recent stud-
ies have shown that while hypothermia (33 degrees Celsius) does
not preserve high-energy phosphate (e.g. ATP. phosphocreatinine)
or prevent accumulation of metabolic waste (e.g. lactate) (Busto
1989), it does confer histopathologic protection from ischaemia
(Busto 1987). Considerable evidence has now accumulated from
neuronal cultures and in vivo animal experiments that excitotoxic
amino acids (particularly glutamate and aspartate) play an impor-
tant role in the evolution of ischaemic brain damage (Benveniste
1989, Choi 1988). Moderate hypothermia is associated with a
decrease in the extracellular levels of glutamate during ischaemia
in rats (Busto 1989) and glycine in rabbits (Baker 1991) and the
beneficial effects of hypothermia is mediate, at least in part, by the
attenuation of release of excitatory amino acids.
Profound hypothermia is already applied in neurosurgery and
open-heart surgery to counter the effects of cerebral hypoxia (Chy-
atte 1989, Saccani 1992) and in severe closed head injury mod-
erate (33 - 32 degrees Celsius) hypothermia appears to improve
outcome (Marion 1993, Marion 1997, Signorini 1999). Although
recent studies in acute stroke patients have shown an association
between body temperature and prognosis (Reith 1996, Azzimondi
1995, Castillo 1994) insufficient information is currently avail-
able in humans to explain and quantify any protective effect of hy-
pothermia and the detrimental effect of hyperthermia on neuro-
logical damage after global or focal cerebral ischaemia. Also some
temperature lowering agents, like non steroidal anti-inflamma-
tory drugs, have antiplatelet activity and could increase the risk of
bleeding in acute ischaemic and haemorrhagic stroke (IST 1997,
CAST 1997). Other risks associated with induced hypothermia
are mainly, sepsis, pneumonia and coagulopathy (Schubert 1995).
This systematic review aims to assess the relationship between im-
posed changes in body temperature and outcome after acute stroke
and determine whether there is any clear evidence that cooling
therapy of any kind is beneficial, or whether the intervention is
sufficiently promising to merit further trials.
O B J E C T I V E S
To determine whether cooling (with antipyretic drugs or with
physical devices) is safe and effective when applied to patients with
acute ischaemic stroke and primary intracerebral haemorrhage.
We wished to test the hypotheses.
(1) That cooling therapy reduces the risk of a “poor-outcome” (ie
being dead or dependent on others in activities of daily living)
several months after stroke.
(2) That cooling therapy increases the risk of intracranial haem-
orrhage (in patients with ischaemic stroke), rebleeding in patients
with primary intracerebral haemorrhage, and extracranial bleed-
ing.
(3) That cooling therapy increases the risk of pneumonia and
coagulopathy.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomised controlled trials (RCT) and controlled clinical trials
(CCT) of cooling versus control (placebo or open control) were
considered eligible.
Types of participants
Patients of any age or sex treated up to two weeks after an acute
ischaemic stroke (CT scan or MRI demonstrates an infarction or
is normal) or primary intracerebral haemorrhage (CT scan orMRI
demonstrates intracerebral haemorrhage).
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Types of intervention
Cooling therapy (therapy given by physical devices or antipyretic
drugs primarily to lower body temperature independently of basal
temperature at the beginning of treatment).
(a) Physical cooling: fluid-filled cooling blanket, ice-water lavage,
’bear-hugger’ air-cooling device, cold infusions or any combina-
tion of above, or other methods.
(b) Chemical cooling (antipyretic drugs) - non steroidal anti-in-
flammatory drugs (aspirin more than 500 mg three times a day or
equivalent doses of other anti-inflammatory drugs (Cyclo-oxyge-
nase inhibitors), paracetamol and acetominophen - by any route.
Types of outcome measures
(1) Poor outcome at the end of follow-up. This is defined as death
or dependency, as measured by the Rankin or Barthel scales, or
another method by which it is clear how many people are depen-
dent and how many are independent. Many would regard this as
the most important outcome since the aim of treatment should
be not only to prevent death but to prevent serious disability in
survivors.
(2) Death from all causes (i) within one month, and (ii) during
the whole follow-up period.
(3) Intracranial haemorrhage (both symptomatic and asymp-
tomatic) demonstrated by CT or MR scan, or autopsy
(4) Extracranial haemorrhage.
(5) Frequency of other complications such as pneumonia, coagu-
lopathy, or other serious adverse events during treatment and fol-
low-up period.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Stroke Group methods used in reviews.
This review has drawn on the search strategy developed for
the Stroke Group as a whole. All possibly relevant trials were
identified in the Specialised Register of Controlled Trials (see
Review Group Details for more information). The Register was
last searched by the Review Group Coordinator for this review
in March 1999 using a search strategy designed to identify all
relevant trials. Additional searches of Medline and EMBASE
were made to supplement the Stroke Group general strategy.
Stroke-specific terms from the search strategy were combined
with the following controlled vocabulary and free text terms:
MEDLINE (Ovid). Years searched 1966-November 1998
MeSHTerms: ExpBODYTEMPERATURE;TEMPERATURE;
COLD; HYPOTHERMIA; HYPOTHERMIA, INDUCED;
FEVER; CRYOTHERAPY
Text words: Hypothermia; cold$; cool$; temperature$
EMBASE (Ovid). Years searched 1980-November 1998
ENTREE Headings: Exp TEMPERATURE; LOW
TEMPERATURE PROCEDURES; CRYOTHERAPY;
INDUCED HYPOTHERMIA; PROFOUND INDUCED
HYPOTHERMIA; HYPOTHERMIA.
Text words: Hypothermia; cold$; cool$; temperature$.
Additionally citations in the reference lists from publications
identified as mentioned above were checked.
Unpublished (or published) work on cooling therapy in acute
stroke was checked in personal contacts with investigators
interested in stroke during meetings.
We contacted the following pharmaceutical companies to
identify further published, unpublished or ongoing studies: Bayer
(Aspirin), Smithkline Beecham (Paracetamol, Nabumetone),
Parke-Daves (Meclofenamate sodium), Upsamedica (Niflumic
acid), Diamant (Tiaprofenic acid), Sigma (Tolfenamic acid),
Medibial (Acemetacine), Jansen-Cilag (Naproxen), Searle / Geig
(Diclofenac), Wyeth (Etodolac. Fentiazac), Bial (Etofenamato),
Basi (Fenbufen), Helsinn (Fentiazac, Nimesulid), Knoll
(Flurbiprofen, Ibuprofen), Upjohn (Ibuprofen), Merck, Sharp
& Dohm (Indomethacin, Sulindac), Alter (ketoprofen), Byk
(Lonazolac), Pfizer (Piroxicam), Roche (Tenoxicam), Delta
(Proglumetacina) - and Manufacturers of cooling equipment -
Cincinnati Sub-Zero Products, Inc., Helsinn Healthcare).
M E T H O D S O F T H E R E V I E W
Two of us (MC,MV) independently searched for RCTs and CCTs
for inclusion in the review but found none. If any are found in the
future we plan that: disagreement will be resolved by discussion,
the same two reviewers will assess the methodological quality of
each trial, no scoring system will be used to assess the quality
of each but details of randomisation method, including whether
intention-to-treat analysis were possible from the published data,
the number of patients lost to follow-up and if there was a blinded
outcome assessment will be checked; data will be independently
extracted by the same two reviewers and cross-checked; any
discrepancies will be discussed and decisions documented; from
the papers we will collect data on: age; gender; stroke type and
delay since stroke; type dosing procedure and route of antipyretic
drug, physical cooling method, lowest body temperature attained,
time between initial symptoms and cooling, the duration that
cooling was applied, neurological deterioration, mortality and
morbidity details. For RCTs and quasi-randomised trials we will
test for heterogeneity and calculate a weighted estimate of the
typical treatment effect across trials (odds ratio). We will also
perform sensitivity analysis, as appropriate, comparing firstly truly
randomised and quasi-randomised trials, and secondly placebo
and open controlled trials. Analysis will be made for all strokes and
independently for ischaemic and haemorrhagic strokes. Analysis
alsowill bemade for all types of cooling therapy and independently
for physical cooling and chemical cooling for the following ranges
of body temperature: more or equal to 37 degrees Celsius; more or
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equal to 36 degrees Celsius and less than 37 degrees Celsius; more
or equal to 35 degrees Celsius and less than 36 degrees Celsius; less
than 35 degrees Celsius. All analyses will be based on “intention-
to-treat” principle where possible. If the published information
doesn’t allow an intention-to-treat analysis we will contact the
authors to get as complete follow-up as possible on all randomised
patients for the originally proposed period of follow-up. If the
Rankin scale or Barthel scale scores are not available we will define
poor-outcome based on the clinical information. A poor outcome
will be considered if the patient requires a high level of supported
care.
This review was prepared using the Cochrane software package
RevMan version 3.1.
D E S C R I P T I O N O F S T U D I E S
No completed trials of physical or chemical cooling therapy in
acute ischaemic stroke or primary intracerebral haemorrhage were
identified. Fifteen trials of aspirin in acute stroke were identified,
but none used an antipyretic dose. These trials were reviewed by
two of us (MC,MV). No completed trials with other non steroidal
anti-inflammatory drugs in acute stroke were identified. One of
us (MC) reviewed 1864 titles and abstracts as a result of MED-
LINE search and 1701 titles and abstracts as a result of EMBASE
search. A randomised placebo controlled clinical trial of metami-
zol (2000 mg three times a day, intravenous) is currently underway
and should be finished by the end of 1999 (ATIS 1998). Metami-
zol is a Pyrazolon derivative and considered in the group of the
non steroidal anti-inflammatory drugs with antipyretic, analgesic
and anti-inflammatory properties. A feasibility and safety study
on physical cooling for a period of six hours by the “forced air
” method in acute stroke showed that modest hypothermic ther-
apy (body temperature 35.5 - 36 degrees Celsius) does not seems
to be harmful, as it is not associated with increased frequency of
complications or increased mortality (Kammersgaard 1999). Also
moderate (33 degrees Celsius) hypothermia by cooling blankets
and cool ventilator air fanning methods, prolonged for 48 - 72
hours is not associated with severe side effects (Schwab 1998).
M E T H O D O L O G I C A L Q U A L I T Y
Not applicable
R E S U L T S
Not applicable
D I S C U S S I O N
We did not identify any completed randomised trials of physical
or chemical cooling methods in acute stroke. Although there have
been trials of aspirin, none used an antipyretic dose. A trial of a
chemical cooling agent (ATIS 1998) is underway. Physical cooling
methods appear feasible in acute stroke (Kammersgaard 1999) and
in head injury (Signorini 1999), so a randomised controlled trial
in acute stroke is justified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are no completed randomised controlled trials of physical
or chemical cooling in acute ischaemic stroke or primary intrac-
erebral haemorrhage. Routine application of such therapy cannot
be recommended at present.
Implications for research
Experimental studies show that hypothermia confers protection
against the neuronal injury produced by cerebral ischaemia. In
humans hypothermia is already applied in neurosurgery and open-
heart surgery. Also in severe closed head injury hypothermia seems
to hasten neurological recovery and the outcome. Hence, trials
with physical or chemical cooling, as a neuroprotection, in humans
with acute stroke are needed.
P O T E N T I A L C O N F L I C T O F
I N T E R E S T
None
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T A B L E S
Characteristics of ongoing studies
Study ATIS 1998
Trial name or title Antitermic Ischemic Stroke
Participants Acute ischaemic stroke until 48 hours after initial symptoms and body temperature between 37 degrees C and
38 degrees C.
Size: 250 patients
Interventions Metamizol (2000mg three times a day, intravenous) vs placebo. Metamizol is a pyrazolon derivative and consid-
ered in the group of the non steroidal anti-inflammatory drugs with antipyretic, analgesic and anti-inflammatory
properties
Outcomes Score on Scandinavian Stroke Scale at 7, 30 and 90 days after stroke and infarction volume at 90 days
Starting date October 1998
Contact information Dr Jose Castillo, Dept of Neurology, Hospital Xeral de Galicia, 15705 Santiago de Compostela, Spain. Fax: 34
81 570102; email: mecasti@usc.es
Notes
G R A P H S A N D O T H E R T A B L E S
This review has no analyses.
I N D E X T E R M S
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